Author correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Author
Wei, Andrew HPanayiotidis, Panayiotis
Montesinos, Pau
Laribi, Kamel
Ivanov, Vladimir
Kim, Inho
Novak, Jan
Stevens, Don A
Fiedler, Walter
Pagoni, Maria
Bergeron, Julie
Ting, Stephen B
Hou, Jing-Zhou
Anagnostopoulos, Achilles
McDonald, Andrew
Murthy, Vidhya
Yamauchi, Takahiro
Wang, Jianxiang
Chyla, Brenda
Sun, Yan
Jiang, Qi
Mendes, Wellington
Hayslip, John
DiNardo, Courtney D
Publication date
2021-10-26Subject
Haematology
Metadata
Show full item recordAbstract
No abstract availableCitation
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J. 2021 Oct 26;11(10):171. doi: 10.1038/s41408-021-00565-6. Erratum for: Blood Cancer J. 2021 Oct 1;11(10):163Type
CorrigendumAdditional Links
http://www.nature.com/bcj/index.htmlPMID
34702803Journal
Blood Cancer JournalPublisher
Nature Publishing Groupae974a485f413a2113503eed53cd6c53
10.1038/s41408-021-00565-6